Paulina M. Gutkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paulina M. Gutkin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Susan M. Hiniker
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
9 shared publications Rie von Eyben
Department of Radiation Oncology Stanford University Stanford California USA
6 shared publications- Kathleen C. Horst
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
5 shared publications Sarah S. Donaldson
Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California
4 shared publications- Clare E. Jacobson
Department of Surgery, University of Michigan, Ann Arbor, Michigan
3 shared publications Cecil M. Benitez
Department of Medicine, Highland Hospital, Oakland, CA
2 shared publications
Latest Publications
- 6 September 2024
- Published byĀ ElsevierĀ inĀ The American Journal of Surgery
- Vol.Ā 242, 115951
In the Era of pass/fail: Medical student perceptions on optimizing their surgical residency applications
- 6 September 2024
- Published byĀ ElsevierĀ inĀ The American Journal of Surgery
- Vol.Ā 242, 115951
In the Era of pass/fail: Medical student perceptions on optimizing their surgical residency applications
- 27 October 2022
- Published byĀ WileyĀ inĀ Journal of Medical Imaging and Radiation Oncology
- Vol.Ā 67 Ā (1) , 81-88
Time to resolution of iodineā123 metaiodobenzylguanidine (123IāMIBG) avidity and local control outcomes for highārisk neuroblastoma following radiation therapy
Introduction I-123-MIBG scan is used in neuroblastoma (NB) to monitor treatment response. Time to resolution of I-123-MIBG avidity after radiation therapy (RT) is unknown. We sought to determine time to resolution of I-123-MIBG avidity after RT and local failure (LF) rate. Methods We performed a retrospective review of children with high-risk NB who underwent I-123-MIBG scans pre- and post-RT from 2003 to 2019. Time from RT to resolution of I-123-MIBG activity was analysed. LF and cumulative incidence of local progression (CILP) after RT stratified by site, presence of residual disease and use of boost RT were determined. Results Forty-two patients with median age 3.9 years (1.9-4.7 years) were included, with median follow-up time 3.9 years (1.4-6.9). Eighty-six lesions were treated with RT to median dose of 21.6 Gy. Eighteen of 86 lesions were evaluable for time to resolution of MIBG avidity after RT, with median resolution time of 78 days (36-208). No LF occurred among 26 patients who received RT to primary sites after GTR, versus 4/12 (25%) patients treated with residual primary disease. 2-year CILP was 19% (12% primary disease 25% metastatic disease (P = 0.18)). 2-year CILP for non-residual primary, residual primary, non-residual metastatic and residual metastatic lesions was 0%, 42%, 11% and 30% respectively (P = 0.01) and for boosted and non-boosted residual lesions was 29% and 35% (P = 0.44). Conclusion Median time to MIBG resolution after RT was 78 days. Primary lesions without residual disease had excellent local control. LF rate was higher after RT for residual disease, with no benefit for boost RT.
- 27 October 2022
- Published byĀ WileyĀ inĀ Journal of Medical Imaging and Radiation Oncology
- Vol.Ā 67 Ā (1) , 81-88
Time to resolution of iodineā123 metaiodobenzylguanidine (123IāMIBG) avidity and local control outcomes for highārisk neuroblastoma following radiation therapy
Introduction I-123-MIBG scan is used in neuroblastoma (NB) to monitor treatment response. Time to resolution of I-123-MIBG avidity after radiation therapy (RT) is unknown. We sought to determine time to resolution of I-123-MIBG avidity after RT and local failure (LF) rate. Methods We performed a retrospective review of children with high-risk NB who underwent I-123-MIBG scans pre- and post-RT from 2003 to 2019. Time from RT to resolution of I-123-MIBG activity was analysed. LF and cumulative incidence of local progression (CILP) after RT stratified by site, presence of residual disease and use of boost RT were determined. Results Forty-two patients with median age 3.9 years (1.9-4.7 years) were included, with median follow-up time 3.9 years (1.4-6.9). Eighty-six lesions were treated with RT to median dose of 21.6 Gy. Eighteen of 86 lesions were evaluable for time to resolution of MIBG avidity after RT, with median resolution time of 78 days (36-208). No LF occurred among 26 patients who received RT to primary sites after GTR, versus 4/12 (25%) patients treated with residual primary disease. 2-year CILP was 19% (12% primary disease 25% metastatic disease (P = 0.18)). 2-year CILP for non-residual primary, residual primary, non-residual metastatic and residual metastatic lesions was 0%, 42%, 11% and 30% respectively (P = 0.01) and for boosted and non-boosted residual lesions was 29% and 35% (P = 0.44). Conclusion Median time to MIBG resolution after RT was 78 days. Primary lesions without residual disease had excellent local control. LF rate was higher after RT for residual disease, with no benefit for boost RT.
- 1 May 2021
- Published byĀ American Society of Clinical Oncology (ASCO)Ā inĀ JCO Oncology Practice
- Vol.Ā 17 Ā (5) , e603-e613
Impact of Insurance on Stage of Breast Cancer Presentation for Different Races and Ethnicities
Survival in breast cancer is largely stage-dependent. Lack of insurance and Medicaid have been associated with later-stage breast cancer, but it is unknown to what degree this association varies by race or ethnicity. We conducted a retrospective single-institution cohort analysis of women undergoing breast radiotherapy from 2012 to 2017 (n = 1,019). Patients were categorized as having private insurance (n = 540), Medicare (n = 332), Medicaid (n = 122), or self-pay (n = 25). Ordinal logistic regression analysis identified variables associated with later-stage presentation, including age, race or ethnicity, insurance, the interaction between insurance and race or ethnicity, body mass index, education, and language. The association between insurance and breast cancer stage varied on the basis of a patient's race or ethnicity (P = .0114). White and Asian patients with Medicaid had significantly higher odds of later-stage breast cancer than those with private insurance (White odds ratio [OR], 2.10; 95% CI, 1.02 to 4.34; Asian OR, 3.22; 95% CI, 1.56 to 6.67). However, the inverse was true for Hispanic patients who had lower odds of later-stage disease with Medicaid than private insurance (OR, 0.36; 95% CI, 0.16 to 0.90). Hispanic patients with Medicaid had lower odds than either White or Asian patients with Medicaid. These findings persisted across all ages. The association between insurance and later-stage presentation is significantly influenced by race or ethnicity. Medicaid was generally associated with later-stage breast cancer diagnosis, but this was not true across all races and ethnicities. Although White and Asian patients with Medicaid presented with later stage, Hispanic patients fared better with Medicaid than private insurance. Future work should investigate how Medicaid is successfully targeting Hispanic patients in breast cancer care.
- 1 May 2021
- Published byĀ American Society of Clinical Oncology (ASCO)Ā inĀ JCO Oncology Practice
- Vol.Ā 17 Ā (5) , e603-e613
Impact of Insurance on Stage of Breast Cancer Presentation for Different Races and Ethnicities
Survival in breast cancer is largely stage-dependent. Lack of insurance and Medicaid have been associated with later-stage breast cancer, but it is unknown to what degree this association varies by race or ethnicity. We conducted a retrospective single-institution cohort analysis of women undergoing breast radiotherapy from 2012 to 2017 (n = 1,019). Patients were categorized as having private insurance (n = 540), Medicare (n = 332), Medicaid (n = 122), or self-pay (n = 25). Ordinal logistic regression analysis identified variables associated with later-stage presentation, including age, race or ethnicity, insurance, the interaction between insurance and race or ethnicity, body mass index, education, and language. The association between insurance and breast cancer stage varied on the basis of a patient's race or ethnicity (P = .0114). White and Asian patients with Medicaid had significantly higher odds of later-stage breast cancer than those with private insurance (White odds ratio [OR], 2.10; 95% CI, 1.02 to 4.34; Asian OR, 3.22; 95% CI, 1.56 to 6.67). However, the inverse was true for Hispanic patients who had lower odds of later-stage disease with Medicaid than private insurance (OR, 0.36; 95% CI, 0.16 to 0.90). Hispanic patients with Medicaid had lower odds than either White or Asian patients with Medicaid. These findings persisted across all ages. The association between insurance and later-stage presentation is significantly influenced by race or ethnicity. Medicaid was generally associated with later-stage breast cancer diagnosis, but this was not true across all races and ethnicities. Although White and Asian patients with Medicaid presented with later stage, Hispanic patients fared better with Medicaid than private insurance. Future work should investigate how Medicaid is successfully targeting Hispanic patients in breast cancer care.
- 1 October 2020
- Published byĀ ElsevierĀ inĀ Clinical Breast Cancer
- Vol.Ā 20 Ā (5) , 431-438
Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery
- 1 October 2020
- Published byĀ ElsevierĀ inĀ Clinical Breast Cancer
- Vol.Ā 20 Ā (5) , 431-438
Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery
- 1 April 2020
- Published byĀ SAGE PublicationsĀ inĀ Journal of Adolescent and Young Adult Oncology
- Vol.Ā 9 Ā (2) , 166-171
Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience
Purpose: To evaluate outcomes and central nervous system (CNS) relapse in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), who underwent total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (allo-SCT). Methods: A total of 136 AYA patients with ALL who received TBI before allo-SCT between 1998 and 2018 were reviewed. Twenty patients received cranial radiation in their initial treatment before conditioning for transplant and were excluded. Competing risk analysis was used to estimate the cumulative incidence of relapse. Kaplan-Meier and log-rank tests were used to calculate overall survival (OS) and to identify factors predictive of relapse. OS and time to relapse were calculated from date of allo-SCT. Results: One hundred sixteen patients were included in the analysis. Median age was 27 years and median follow-up time was 42 months. Twenty-six patients suffered a disease relapse and 49 died, 26 of posttransplantation complications. The median time to relapse was 7 months and the 5-year OS was 60%. Seven patients had a CNS relapse: 4 of 20 patients (25%) with pre-SCT CNS disease had a post-allo-SCT CNS relapse compared to 3 of 97 (3.1%) without pre-SCT CNS disease. Median time to CNS relapse was 7 months. Patients with post-SCT CNS relapse had median OS of 19 months. Conclusions: AYA patients with CNS disease who undergo an allo-SCT have a high rate of CNS relapse. The addition of additional CNS-directed therapy to transplant protocols warrants further investigation.
- 1 April 2020
- Published byĀ SAGE PublicationsĀ inĀ Journal of Adolescent and Young Adult Oncology
- Vol.Ā 9 Ā (2) , 166-171
Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience
Purpose: To evaluate outcomes and central nervous system (CNS) relapse in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), who underwent total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (allo-SCT). Methods: A total of 136 AYA patients with ALL who received TBI before allo-SCT between 1998 and 2018 were reviewed. Twenty patients received cranial radiation in their initial treatment before conditioning for transplant and were excluded. Competing risk analysis was used to estimate the cumulative incidence of relapse. Kaplan-Meier and log-rank tests were used to calculate overall survival (OS) and to identify factors predictive of relapse. OS and time to relapse were calculated from date of allo-SCT. Results: One hundred sixteen patients were included in the analysis. Median age was 27 years and median follow-up time was 42 months. Twenty-six patients suffered a disease relapse and 49 died, 26 of posttransplantation complications. The median time to relapse was 7 months and the 5-year OS was 60%. Seven patients had a CNS relapse: 4 of 20 patients (25%) with pre-SCT CNS disease had a post-allo-SCT CNS relapse compared to 3 of 97 (3.1%) without pre-SCT CNS disease. Median time to CNS relapse was 7 months. Patients with post-SCT CNS relapse had median OS of 19 months. Conclusions: AYA patients with CNS disease who undergo an allo-SCT have a high rate of CNS relapse. The addition of additional CNS-directed therapy to transplant protocols warrants further investigation.
- 29 March 2020
- Published byĀ WileyĀ inĀ International Wound Journal
- Vol.Ā 17 Ā (4) , 910-915
Erythema of the skin after breast radiotherapy: It is not always recurrence
Recurrence of breast cancer is a predominant fear for patients who were treated for breast cancer. Acute and late dermatologic effects of radiotherapy are not uncommon and could have similar characteristics to breast cancer recurrence. Thus, it is important to highlight key differences between the clinical and histologic presentations of radiation effects and recurrence. Herein, we present two patients who presented with late dermatologic effects of radiotherapy months to years after treatment, neither of whom had workup consistent with cancer recurrence. We provide clinical and microscopic descriptions of each case and provide a review to differentiate various dermatologic conditions. This report aims to outline potential late dermatologic effects of radiation treatment and emphasise that changes in the breast do not always signal breast cancer recurrence.
- 29 March 2020
- Published byĀ WileyĀ inĀ International Wound Journal
- Vol.Ā 17 Ā (4) , 910-915
Erythema of the skin after breast radiotherapy: It is not always recurrence
Recurrence of breast cancer is a predominant fear for patients who were treated for breast cancer. Acute and late dermatologic effects of radiotherapy are not uncommon and could have similar characteristics to breast cancer recurrence. Thus, it is important to highlight key differences between the clinical and histologic presentations of radiation effects and recurrence. Herein, we present two patients who presented with late dermatologic effects of radiotherapy months to years after treatment, neither of whom had workup consistent with cancer recurrence. We provide clinical and microscopic descriptions of each case and provide a review to differentiate various dermatologic conditions. This report aims to outline potential late dermatologic effects of radiation treatment and emphasise that changes in the breast do not always signal breast cancer recurrence.
- Open Access
- 12 February 2020
- Published byĀ Taylor & FrancisĀ inĀ Melanoma Management
- Vol.Ā 7 Ā (1) , 7-16
Durability of Response in Metastatic Melanoma Patients after Combined Treatment with Radiation Therapy and Ipilimumab
Aim: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term...
- 12 February 2020
- Published byĀ Taylor & FrancisĀ inĀ Melanoma Management
- Vol.Ā 7 Ā (1) , 7-16
Open AccessDurability of Response in Metastatic Melanoma Patients after Combined Treatment with Radiation Therapy and Ipilimumab
Aim: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term...
- 30 January 2020
- Published byĀ Hindawi LimitedĀ inĀ The Breast Journal
- Vol.Ā 26 Ā (7) , 1475-1477
Health mindset is associated with anxiety and depression in patients undergoing treatment for breast cancer
Click on the article title to read more.
- 30 January 2020
- Published byĀ Hindawi LimitedĀ inĀ The Breast Journal
- Vol.Ā 26 Ā (7) , 1475-1477
Health mindset is associated with anxiety and depression in patients undergoing treatment for breast cancer
Click on the article title to read more.
- 3 December 2019
- Published byĀ ElsevierĀ inĀ International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol.Ā 108 Ā (1) , 268-276
Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer
- 3 December 2019
- Published byĀ ElsevierĀ inĀ International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol.Ā 108 Ā (1) , 268-276
Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer
- 12 August 2019
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Pediatric Hematology/Oncology
- Vol.Ā 42 Ā (8) , e807-e809
Successful Full-term Pregnancies After High-dose Pelvic Radiotherapy for Ewing Sarcoma: A Case Report
Survivors of childhood cancer are at risk of long-term sequelae that arise as a consequence of cancer treatment. Radiation and chemotherapy treatment in pediatric female patients can have detrimental impacts on fertility, particularly in those with pelvic tumor involvement. We report 2 successful natural full-term pregnancies with vaginal delivery in a woman 12 years after biopsy, irradiation (55.5 Gy), and multi-agent chemotherapy for treatment of pelvic Ewing sarcoma. Both children were born healthy, with no complications in pregnancy or delivery. Fertility preservation and risk assessment following chemotherapy/radiation therapy is evolving, providing new data to effectively counsel and treat young women.
- 12 August 2019
- Published byĀ Wolters Kluwer HealthĀ inĀ Journal of Pediatric Hematology/Oncology
- Vol.Ā 42 Ā (8) , e807-e809
Successful Full-term Pregnancies After High-dose Pelvic Radiotherapy for Ewing Sarcoma: A Case Report
Survivors of childhood cancer are at risk of long-term sequelae that arise as a consequence of cancer treatment. Radiation and chemotherapy treatment in pediatric female patients can have detrimental impacts on fertility, particularly in those with pelvic tumor involvement. We report 2 successful natural full-term pregnancies with vaginal delivery in a woman 12 years after biopsy, irradiation (55.5 Gy), and multi-agent chemotherapy for treatment of pelvic Ewing sarcoma. Both children were born healthy, with no complications in pregnancy or delivery. Fertility preservation and risk assessment following chemotherapy/radiation therapy is evolving, providing new data to effectively counsel and treat young women.